Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/31/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. John J.P. Kastelein

Wrong Dr. John J.P. Kastelein?

Professor of Medicine At the Depa...

Phone: +31 *********
Local Address: Netherlands
UAMS
4301 West Markham Street, Slot 718
Little Rock , Arkansas 72205
United States

Company Description: UAMS aims to be a 'full-service partner' and its primary goal is to help current and future managers in the private, public and non-profit sector fulfil their...   more
Background

Employment History

  • Professor of Medicine, Strategic Chair of Genetics of Cardiovascular Disease
    UAMS
  • Member, Department of Vascular Medicine
    UAMS
  • Lead Researcher
    ENHANCE
  • Part of the Department of Vascular Medicine
    Lipid Research Clinic
  • Professor of Medicine and Chairman of the Department of Vascular Medicine
    Academic Medical Center
  • Founder of the Lipid Research Clinic
    Academic Medical Center
  • Member, Department of Vascular Medicine
    Academic Medical Center
  • President
    Dutch Atherosclerosis Society
  • President
    National Scientific Committee on Familial Hypercholesterolemia

Board Memberships and Affiliations

  • Board Member
    International Task Force for CHD Prevention
  • Member
    European Atherosclerosis Society
  • Number of Executive and Steering Committees
    IDEAL Scanners & Systems Inc
  • Chairman, Scientific and Clinical Advisory Board
    Dezima Pharma BV
  • Founder
    Dezima Pharma BV
  • Member
    Royal Dutch Society for Medicine & Physics
  • Member
    Council for Basic Science of the American Heart Association
  • Number of Executive and Steering Committees
    ENHANCE
  • Executive Board
    International Atherosclerosis Society
  • Founder
    Lipid Research Clinic

Education

  • M.D.
  • Ph.D
  • medical degree and internal medicine
  • MD
  • PhD
  • Ph.D.
  • PhD et
  • medical degree
  • doctorate ( cum laude )
177 Total References
Web References
CETP as a Therapeutic Target | NLA vClinic
lipid.realcme.com, 31 Jan 2015 [cached]
John J.P. Kastelein, MD PhD, FESC Professor of Medicine Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam
...
John J.P. Kastelein, MD PhD, FESC John J.P. Kastelein (1954) is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof.Dr.
...
Dr. Kastelein was president of the Dutch Atherosclerosis Society (DAS) until 2009 and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society. He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS) and Fellow of the European Society of Cardiology. Professor Kastelein was also one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders. AMT has recently (summer 2007) enjoyed a successful Initial Public Offering (IPO) at EuroNext in Amsterdam. The results of the first successful human gene therapy trial were widely publicized in the media and are published in ATVB in 2008. Professor Kastelein's current research interests can be found in the etiology, diagnosis, prevention and treatment ofhypertriglyceridaemia, hypercholesterolaemia and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. He has published over 680 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 72. Dr. Kastelein is an investigator of the Bloodomics and CardioGenics consortia, two large European Union supported endavours under the Framework Programme 7, that aim to elucidate the molecular basis of atherosclerosis and premature coronary disease. Besides the scientific programmes aimed at the etiology of atherogenesis, Dr. Kastelein also serves on a number of executive and steering committees of large intervention studies, including the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008) and JUPITER (2008) are published in the New England Journal of Medicine, IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet. Since recently, Dr. Kastelein has developed the use of non-invasive B-mode ultrasound as well as Nuclear Magnetic Resonance (MRI) studies of the carotid arteries for the diagnosis and assessment of novel treatments for atherosclerosis. This has lead to the recognition of the AMC as a leading center for this technique which has recently been exported to a substantial number of academic sites throughout Europe. This has culminated in the set up of NICE, Network of Imaging Centers in Europe of which Dr. Kastelein is the director. Dr. Kastelein's achievements in this field are internationally recognized by numerous invited reviews on this subject. Dr. Kastelein also serves as an International Associate Editor of the European Heart Journal. He has directed 47 postdoctoral theses and currently, he heads a team of 6 internists, 6 postdoctoral fellows, 26 MD PhD students, and a large number of laboratory technicians and clinical trial / study coordinators
Scientific Advisory Board > About Cerenis > Cerenis Therapeutics
www.cerenis.com, 23 Dec 2014 [cached]
John J.P. Kastelein
...
John J.P. Kastelein, M.D., Ph.D
Professor of Medicine, Strategic Chair of Genetics of Cardiovascular Disease, and Chairman of the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam.
Dr. Kastelein is chair of the National Scientific Committee on Familial Hypercholesterolemia (EHC), a member of the Royal Dutch Society for Medicine & Physics, a member of the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society, a board member of the International Task Force for CHD Prevention, a member of the Executive Board of the International Atherosclerosis Society (IAS), and a principal investigator of the Bloodomics and CardioGenics consortia.
Professor Kastelein's current research interests are in hypertriglyceridaemia, hypercholesterolaemia and low-HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease.
...
Dr. Kastelein received his medical degree and internal medicine training in Amsterdam in the 1980s.
Forbion empowering entrepreneurs to foster healthcare innovation
www.forbion.com, 25 Sept 2014 [cached]
John J.P. Kastelein, MD PhD FESC
...
John J.P. Kastelein, MD PhD FESC
Advisor
...
Prof. Kastelein advises Forbion on the cardiovascular and metabolic disease space and presents Forbion with investment opportunities in these fields.
Dr. John Kastelein is professor of medicine, chairman of the department of vascular medicine, and holds the Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. Dr. Kastelein is a member of the Steering Committees of numerous lipid lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for Cardiovascular Diseases and the genetic basis of dyslipidemia. Dr. Kastelein was awarded a doctorate in Medicine (with Honours) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. He is president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and also a Fellow of the European Society of Cardiology (FESC). In 2010 he was awarded the prestigious Dutch Heart Association prize of EUR 1 million and in 2011 the ZonMw Parel for his research in the field of gene therapy.
John J.P. Kastelein, MD PhD FESC
Advisor Phone +31 20 566 6612
Prof. Kastelein advises Forbion on the cardiovascular and metabolic disease space and presents Forbion with investment opportunities in these fields.
Dr. John Kastelein is professor of medicine, chairman of the department of vascular medicine, and holds the Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. Dr. Kastelein is a member of the Steering Committees of numerous lipid lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for Cardiovascular Diseases and the genetic basis of dyslipidemia. Dr. Kastelein was awarded a doctorate in Medicine (with Honours) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. He is president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and also a Fellow of the European Society of Cardiology (FESC). In 2010 he was awarded the prestigious Dutch Heart Association prize of EUR 1 million and in 2011 the ZonMw Parel for his research in the field of gene therapy.
...
The EAS is delighted to announce that the recipient of the Society's prestigious Anitschkow Prize 2014 is Professor John J.P. Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam and Strategic Chair of Genetics of Cardiovascular Disease.
...
Forbion Capital Partners today announced the appointment of Dr Kapil Dhingra, formerly global leader in oncology at Roche, and Prof. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the University of Amsterdam, as Scientific Advsors.
Scientific and Clinical Advisory Boards
www.dezimapharma.com, 14 Oct 2014 [cached]
Prof. John Kastelein, MD, PhD - Chairman Scientific and Clinical Advisory Board Dr. John Kastelein is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam with a research interest in ethiology, diagnosis, prevention and treatment of hypertriglyceridaemia, hypercholesteroleamia and low HDL cholesterol. He is founder of Dezima Pharma and co-founder of UniQure and Xenon Pharma. John is advisor to Large Pharma and biotech companies developing cardiovascular disease drugs and principal investigator and advisor to many of the studies trialing new anti-dyslipidemia compounds, including CETP inhibitors. John is member of several national and international medicine, atherosclerosis and cardiology societies aiming to study, prevent and treat cardiovascular diseases. He has published several hundreds of research papers and handbooks on dyslipidemia.
Grassley's letter cites testy e-mails to ...
timesunion.com, 1 April 2008 [cached]
Grassley's letter cites testy e-mails to Schering-Plough executives from ENHANCE's lead researcher, Dr. John Kastelein.In one last July, Kastelein states that if it is true the study results wouldn't be presented at an upcoming medical conference, "our collaboration is over... this starts smelling like extending the publication for no other (than) political reasons."
Kastelein went further the next day, Grassley wrote.
...
Kastelein said, according to Grassley
Other People with the name "Kastelein":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304